Corton Capital Inc. Makes New $214,000 Investment in LivaNova PLC (NASDAQ:LIVN)

Corton Capital Inc. acquired a new stake in LivaNova PLC (NASDAQ:LIVN) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 4,622 shares of the company’s stock, valued at approximately $214,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Russell Investments Group Ltd. boosted its stake in shares of LivaNova by 17.1% during the 4th quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company’s stock valued at $70,000 after purchasing an additional 219 shares in the last quarter. Sterling Capital Management LLC raised its holdings in LivaNova by 800.6% in the 4th quarter. Sterling Capital Management LLC now owns 1,621 shares of the company’s stock worth $75,000 after acquiring an additional 1,441 shares during the last quarter. Vestcor Inc bought a new position in shares of LivaNova during the fourth quarter valued at $204,000. Optimize Financial Inc purchased a new position in shares of LivaNova during the fourth quarter valued at approximately $208,000. Finally, Inceptionr LLC bought a new position in shares of LivaNova during the 4th quarter valued at $217,000. 97.64% of the stock is owned by institutional investors.

LivaNova Price Performance

Shares of LIVN stock opened at $43.51 on Thursday. The stock’s 50-day moving average is $37.79 and its 200 day moving average is $45.33. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. LivaNova PLC has a 1-year low of $32.48 and a 1-year high of $63.57. The company has a market cap of $2.37 billion, a P/E ratio of 103.60 and a beta of 0.84.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on LIVN shares. Mizuho cut their price target on LivaNova from $70.00 to $60.00 and set an “outperform” rating for the company in a report on Wednesday, February 26th. Stifel Nicolaus dropped their price objective on shares of LivaNova from $72.00 to $60.00 and set a “buy” rating for the company in a report on Wednesday, February 26th. The Goldman Sachs Group reduced their price target on shares of LivaNova from $64.00 to $55.00 and set a “buy” rating on the stock in a research report on Monday, March 3rd. Barclays decreased their price objective on LivaNova from $58.00 to $56.00 and set an “equal weight” rating on the stock in a research report on Friday, March 7th. Finally, StockNews.com raised shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, March 25th. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $61.17.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.